IDRA Shares Outstanding History



Below is a table of the IDRA shares outstanding history going back to 2/26/2010:

Date IDRA Shares Outstanding
2/26/20102.94M
3/31/20102.94M
6/30/20102.94M
9/30/20103.45M
2/25/20113.45M
4/30/20113.45M
7/29/20113.45M
10/15/20113.45M
2/15/20123.45M
4/30/20123.45M
7/17/20123.45M
10/31/20123.46M
1/31/20133.46M
4/15/20133.46M
5/10/20135.65M
7/31/20135.65M
10/31/20137.96M
2/15/201410.30M
4/30/201410.31M
7/15/201410.47M
10/15/201410.73M
2/19/201514.73M
4/15/201514.73M
7/15/201514.77M
10/15/201514.79M
2/15/201615.16M
4/15/201615.16M
7/15/201615.17M
10/28/201618.46M
2/15/201718.64M
4/28/201718.64M
7/31/201718.70M
11/1/201724.36M
2/15/201824.45M
4/30/201827.16M
7/30/201827.16M
7/31/201827.17M
10/31/201827.18M
2/15/201927.62M
4/30/201928.02M
7/31/201928.84M
10/31/201928.87M
2/15/202030.54M
4/30/202033.70M
7/31/202035.20M
10/29/202035.25M
2/28/202142.26M
4/29/202150.03M
8/6/202152.76M
11/8/202152.80M
3/31/202252.92M
5/5/202252.97M
8/9/202253.05M
11/14/202262.36M

Also see: IDRA Market Cap History
IDRA YTD Return
IDRA Historical Shares Outstanding:
+27.15% CAGR
IDRA Historical Shares Outstanding: +27.15% CAGR

Mouse over chart for data details
2/26/2010 ...11/14/2022
Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development, and the commercialization, of drug candidates for rare disease indications characterized by patient populations with unmet medical needs. Co.'s focus is to identify and acquire rights to development and commercial stage rare disease programs through new business development opportunities, including additional alternatives. Co. is evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-Progressive Disease 1 antibody marketed as Opdivo® by Bristol Myers Squibb Company, and ipilimumab for the treatment of multiple solid tumors in a multicohort trial. We show 54 historical shares outstanding datapoints in our coverage of IDRA's shares outstanding history.

Understanding the changing numbers of IDRA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like IDRA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching IDRA by allowing them to research IDRA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree IDRA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Idera Pharmaceuticals (IDRA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

IDXG Shares Outstanding History
IDXX Shares Outstanding History
IDYA Shares Outstanding History
IGAP Shares Outstanding History
IGMS Shares Outstanding History
IIN Shares Outstanding History
IKNA Shares Outstanding History
IKT Shares Outstanding History
ILMN Shares Outstanding History
IMAC Shares Outstanding History
More Healthcare companies »

 

IDRA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.